Clinical Trial Update: Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating pyrotinib in breast cancer patients with poor response to neoadjuvant trastuzumab and pertuzumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN